These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8988956)

  • 21. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Réseau de Recherche et d'Expérimentation Psychopharmacologique.
    Bordet R; Thomas P; Dupuis B
    Am J Psychiatry; 1998 Oct; 155(10):1346-51. PubMed ID: 9766765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    Nemeroff CB; Thase ME;
    J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of St. John's wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial.
    Lecrubier Y; Clerc G; Didi R; Kieser M
    Am J Psychiatry; 2002 Aug; 159(8):1361-6. PubMed ID: 12153829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A fixed-dose clinical trial of fluoxetine in outpatients with major depression.
    Fabre LF; Putman HP
    J Clin Psychiatry; 1987 Oct; 48(10):406-8. PubMed ID: 3312176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Melatonin for the treatment of sleep disturbances in major depressive disorder.
    Dolberg OT; Hirschmann S; Grunhaus L
    Am J Psychiatry; 1998 Aug; 155(8):1119-21. PubMed ID: 9699707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial.
    Hirschmann S; Dannon PN; Iancu I; Dolberg OT; Zohar J; Grunhaus L
    J Clin Psychopharmacol; 2000 Oct; 20(5):556-9. PubMed ID: 11001241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia.
    Hellerstein DJ; Yanowitch P; Rosenthal J; Samstag LW; Maurer M; Kasch K; Burrows L; Poster M; Cantillon M; Winston A
    Am J Psychiatry; 1993 Aug; 150(8):1169-75. PubMed ID: 8328559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder.
    Chouinard G
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):32-7. PubMed ID: 3882679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.
    Feighner JP
    J Clin Psychiatry; 1985 Sep; 46(9):369-72. PubMed ID: 3897204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoxetine versus trazodone in the treatment of outpatients with major depression.
    Debus JR; Rush AJ; Himmel C; Tyler D; Polatin P; Weissenburger J
    J Clin Psychiatry; 1988 Nov; 49(11):422-6. PubMed ID: 3053668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects.
    Isaac MB; Isaac MT
    Hum Psychopharmacol; 2003 Oct; 18(7):569-74. PubMed ID: 14533141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo.
    Stewart JW; Quitkin FM; McGrath PJ; Amsterdam J; Fava M; Fawcett J; Reimherr F; Rosenbaum J; Beasley C; Roback P
    Arch Gen Psychiatry; 1998 Apr; 55(4):334-43. PubMed ID: 9554429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does the addition of pindolol accelerate the response to electroconvulsive therapy in patients with major depression? A double-blind, placebo-controlled pilot study.
    Shiah IS; Yatham LN; Srisurapanont M; Lam RW; Tam EM; Zis AP
    J Clin Psychopharmacol; 2000 Jun; 20(3):373-8. PubMed ID: 10831027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of fluoxetine in nondepressed patients with Huntington's disease.
    Como PG; Rubin AJ; O'Brien CF; Lawler K; Hickey C; Rubin AE; Henderson R; McDermott MP; McDermott M; Steinberg K; Shoulson I
    Mov Disord; 1997 May; 12(3):397-401. PubMed ID: 9159735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind, randomized study to provide safety information on switching fluoxetine-treated patients to paroxetine without an intervening washout period.
    Kreider MS; Bushnell WD; Oakes R; Wheadon DE
    J Clin Psychiatry; 1995 Apr; 56(4):142-5. PubMed ID: 7713852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
    Stark P; Hardison CD
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):53-8. PubMed ID: 3882682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.
    Gougol A; Zareh-Mohammadi N; Raheb S; Farokhnia M; Salimi S; Iranpour N; Yekehtaz H; Akhondzadeh S
    J Psychopharmacol; 2015 May; 29(5):575-81. PubMed ID: 25827645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pindolol augmentation enhances response outcomes in first depressive episodes.
    Portella MJ; de Diego-Adeliño J; Puigdemont D; Pérez-Egea R; Alvarez E; Artigas F; Pérez V
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):516-9. PubMed ID: 19419845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.